Display options
Cite
Takacova M, Bartosova M, Skvarkova L, et al. Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett. 2012;5(1):191-197doi: 10.3892/ol.2012.1001.
Takacova, M., Bartosova, M., Skvarkova, L., Zatovicova, M., Vidlickova, I., Csaderova, L., Barathova, M., Breza, J., Bujdak, P., Pastorek, J., Breza, J., & Pastorekova, S. (2013). Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncology letters, 5(1), 191-197. https://doi.org/10.3892/ol.2012.1001
Takacova, Martina, et al. "Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma." Oncology letters vol. 5,1 (2013): 191-197. doi: https://doi.org/10.3892/ol.2012.1001
Takacova M, Bartosova M, Skvarkova L, Zatovicova M, Vidlickova I, Csaderova L, Barathova M, Breza J, Bujdak P, Pastorek J, Breza J, Pastorekova S. Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol Lett. 2013 Jan;5(1):191-197. doi: 10.3892/ol.2012.1001. Epub 2012 Oct 26. PMID: 23255918; PMCID: PMC3525455.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2013 Jan;5(1):191-197. doi: 10.3892/ol.2012.1001. Epub 2012 Oct 26.

Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.

Oncology letters

Martina Takacova, Maria Bartosova, Lucia Skvarkova, Miriam Zatovicova, Ivana Vidlickova, Lucia Csaderova, Monika Barathova, Jan Breza, Peter Bujdak, Jaromir Pastorek, Jan Breza, Silvia Pastorekova

Affiliations

  1. Department of Molecular Medicine, Institute of Virology and ; Center for Molecular Medicine, Slovak Academy of Sciences;

PMID: 23255918 PMCID: PMC3525455 DOI: 10.3892/ol.2012.1001

Abstract

Carbonic anhydrase IX (CA IX) is regarded as one of the most prominent markers of tumor hypoxia with potential to serve as a diagnostic biomarker, prognostic indicator as well as tumor therapeutic target. The aim of the present study was to perform an in-depth analysis of CA IX expression in blood and tissue samples and to evaluate the significance of CA IX status for different renal cell carcinomas (RCCs). The expression of CA IX was determined in blood and tissue samples from 74 kidney cancer patients using reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), Western blotting (WB) and immunohistochemistry (IHC). The CA IX status was correlated with RCC type and tumor stage. IHC and WB provided evidence for a significantly higher expression of CA IX in clear cell RCC (CCRCC) specimens compared to other RCCs. RT-PCR assay revealed that 32.42% of all RCC patients possess CA9-positive cells in peripheral blood and three-quarters of CA9-positive patients were diagnosed with CCRCC. When the patients were subdivided according to tumor stage, decreased positivity was observed with higher tumor stage (50% in T1 vs. 17% in T3). Serum CA IX levels determined by ELISA were significantly higher in CCRCC patients than in non-CCRCC. A significant association between s-CA IX and CCRCC tumor stage was also determined (T1-87.51 vs. T3-341.98 pg/ml, p=0.046). We demonstrated that the CA IX expression profiles in blood and tissue samples from 74 kidney cancer patients are closely correlated with their histological subtypes. This is the first study reporting CA IX expression in blood and tissue samples from kidney cancer patients determined by four different methods.

References

  1. Int J Cancer. 2008 Jul 15;123(2):395-400 - PubMed
  2. Cancer. 1999 Aug 1;86(3):492-7 - PubMed
  3. Cancer Res. 1997 Jul 15;57(14):2827-31 - PubMed
  4. Cancer Res. 2001 Jul 1;61(13):5215-22 - PubMed
  5. FEBS Lett. 2004 Nov 19;577(3):439-45 - PubMed
  6. Br J Cancer. 2008 Jan 15;98(1):129-36 - PubMed
  7. Urology. 2010 Feb;75(2):257-61 - PubMed
  8. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  9. Nat Genet. 1994 May;7(1):85-90 - PubMed
  10. Br J Cancer. 2005 Nov 28;93(11):1267-76 - PubMed
  11. Clin Cancer Res. 2005 May 15;11(10):3714-21 - PubMed
  12. Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2190-4 - PubMed
  13. BJU Int. 2007 Sep;100(3):556-60 - PubMed
  14. Lung Cancer. 2009 Jun;64(3):271-6 - PubMed
  15. Urol Oncol. 2012 May-Jun;30(3):278-84 - PubMed
  16. Urol Oncol. 2006 Jul-Aug;24(4):287-93 - PubMed
  17. Clin Cancer Res. 2003 Feb;9(2):802-11 - PubMed
  18. J Urol. 2008 Aug;180(2):510-3; discussion 513-4 - PubMed
  19. Br J Cancer. 2003 Sep 15;89(6):1067-71 - PubMed
  20. Urology. 2000 Sep 1;56(3):393-8 - PubMed
  21. Clin Cancer Res. 2010 Oct 1;16(19):4853-63 - PubMed
  22. Anticancer Res. 2010 Jul;30(7):2953-7 - PubMed
  23. Virology. 1992 Apr;187(2):620-6 - PubMed
  24. Urology. 2006 May;67(5):942-5 - PubMed
  25. Ann Clin Biochem. 2011 Mar;48(Pt 2):112-20 - PubMed
  26. Genomics. 1996 May 1;33(3):480-7 - PubMed
  27. Cancer Res. 2000 Dec 15;60(24):7075-83 - PubMed
  28. J Immunol Methods. 2003 Nov;282(1-2):117-34 - PubMed

Publication Types